libre de droit Mirum Pharmaceuticals (NASDAQ:MIRM) develops innovative therapies for rare liver diseases. It focuses on regulating bile acids to address cholestasis, inborn errors of bile acid metabolism, and cholesterol metabolism disorders. MIRM’s portfolio includes Livmarli for Alagille syndrome and progressive familial intrahepatic cholestasis, Cholbam for bile acid synthesis disorders and peroxisomal disorders, and Chenodal for gallstone disease and potentially cerebrotendinous xanthomatosis. Also, ...